Bio-Path Announces Research Collaboration with Leading Oncology Institution

Bio-Path Announces Research Collaboration with Leading Oncology Institution

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, March 8, 2016

Spending on oncology drugs crossed $100 billion in 2014 and the trend is expected to continue. The availability of new treatment options and treatment costs have been the key drivers of growth in oncology spending. Increasing spending on cancer drugs has not surprisingly piqued the interests of major pharmaceutical and biotechnology companies. The likes of Merck & Company (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) have been spending billions of dollars in research on new oncology products. However, the research is not restricted to large cap companies. Several small cap companies in the biotech space are focusing on oncology. One such company is Bio-Path Holdings Inc. (NASDAQ:BPTH).


Based in Bellaire, Texas, Bio-Path is a clinical stage biotechnology company focusing on the development of cancer drugs under a license arrangement. The company is leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. BPTH’s lead product candidate is in a Phase II study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers.

BPTH shares have risen sharply in trading today even as the broader market is struggling. At last check, the stock was trading 4.12% higher at $1.77 on volume of 281,880, which is more than four times the daily average volume.

BPTH shares are gaining in trading today after the company announced that it has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to evaluate BPTH’s clinical pipeline for its ability to modulate pancreatic cancer. The evaluation will include BP1001, BPTH’s lead product candidate.

Jason Fleming, MD, F.A.C.S., professor of surgical oncology within the division of surgery at MD Anderson, will serve as the study’s principal investigator. Dr. Fleming pioneered the first direct xenograft program in gastrointestinal cancer. Dr. Fleming also serves as director of the tissue acquisition and biorepository core for the Pancreas Cancer Research Program at MD Anderson, and is a board certified pancreatic surgeon.

Commenting on the development, Peter Nielsen, President & CEO at Bio-Path, said that the company is honored to collaborate with Dr. Fleming. Nielsen further said that Dr. Fleming’s experience working with pancreatic xenografts makes him uniquely qualified to lead this study and the company looks forward to assessing whether its drug candidates work in this ex vivo model before potentially moving into animal studies.

Share of BPTH have been trading wildly over the last few months but with all the ups and downs, the trend has been higher since last October with shares up about 75% in that time frame.

Copyright © 2016 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Miner Scores with Acquisition of Promising Silver District in Mexico
Mixed Signals: Durable Goods Orders Up, But Not All Sectors Are Soaring
Biotech Steals The Show Following Pre-Clinical Data Announcement
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top